{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:00:30Z","timestamp":1773788430742,"version":"3.50.1"},"reference-count":134,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Since the association of microalbuminuria (MAU) with cardiovascular (CV) risk was described, a huge number of reports have emerged. MAU is a specific integrated marker of CV risk and targets organ damage in patients with hypertension, chronic kidney disease (CKD), and diabetes and its recognition is important for identifying patients at a high or very high global CV risk. The gold standard for diagnosis is albumin measured in 24-hour urine collection (normal values of less than 30 mg\/day, MAU of 30 to 300 mg\/day, macroalbuminuria of more than 300 mg\/day) or, more practically, the determination of urinary albumin-to-creatinine ratio in a urine morning sample (30 to 300 mg\/g). MAU screening is mandatory in individuals at risk of developing or presenting elevated global CV risk. Evidence has shown that intensive treatment could turn MAU into normoalbuminuria. Intensive treatment with the administration of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, in combination with other anti-hypertensive drugs and drugs covering other aspects of CV risk, such as mineralocorticoid receptor antagonists, new anti-diabetic drugs, and statins, can diminish the risk accompanying albuminuria in hypertensive patients with or without CKD and diabetes.<\/ns4:p>","DOI":"10.12688\/f1000research.17212.1","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T10:15:07Z","timestamp":1568888107000},"page":"1659","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Microalbuminuria and cardiorenal risk: old and new evidence in different populations"],"prefix":"10.12688","volume":"8","author":[{"given":"Diego Francisco","family":"M\u00e1rquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Ruiz-Hurtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6278-7951","authenticated-orcid":false,"given":"Luis","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2019,9,19]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"356-60","DOI":"10.1056\/NEJM198402093100605","article-title":"Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.","volume":"310","author":"C Mogensen","year":"1984","journal-title":"N Engl J Med."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"279-306","DOI":"10.1007\/5584_2016_85","article-title":"Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria.","volume":"956","author":"G Mul\u00e8","year":"2017","journal-title":"Adv Exp Med Biol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"2073-81","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.","volume":"375","author":"K Matsushita","year":"2010","journal-title":"Lancet."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"S165-8","DOI":"10.1097\/01.asn.0000034496.63958.f8","article-title":"The kidney as a sensor of cardiovascular risk in essential hypertension.","volume":"13 Suppl 3","author":"L Ruilope","year":"2002","journal-title":"J Am Soc Nephrol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"969-75","DOI":"10.1161\/CIRCULATIONAHA.105.538132","article-title":"Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study.","volume":"112","author":"J Arnl\u00f6v","year":"2005","journal-title":"Circulation."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"581-90","DOI":"10.2215\/CJN.03190906","article-title":"Microalbuminuria and cardiovascular disease.","volume":"2","author":"M Weir","year":"2007","journal-title":"Clin J Am Soc Nephrol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"205-26","DOI":"10.1053\/j.ajkd.2009.04.029","article-title":"Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.","volume":"54","author":"A Levey","year":"2009","journal-title":"Am J Kidney Dis."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"572-81","DOI":"10.2337\/diacare.18.4.572","article-title":"Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion.","volume":"18","author":"C Mogensen","year":"1995","journal-title":"Diabetes Care."},{"key":"ref-9","doi-asserted-by":"crossref","first-page":"2034-8","DOI":"10.1093\/clinchem\/33.11.2034","article-title":"Selecting the optimum specimen for assessing slight albuminuria, and a strategy for clinical investigation: novel uses of data on biological variation.","volume":"33","author":"J Howey","year":"1987","journal-title":"Clin Chem."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"436-43","DOI":"10.1681\/ASN.2008030292","article-title":"First morning voids are more reliable than spot urine samples to assess microalbuminuria.","volume":"20","author":"E Witte","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"24-38","DOI":"10.1373\/clinchem.2008.106567","article-title":"Current issues in measurement and reporting of urinary albumin excretion.","volume":"55","author":"W Miller","year":"2009","journal-title":"Clin Chem."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"1355-60","DOI":"10.1681\/ASN.2010010063","article-title":"Comparison of different measures of urinary protein excretion for prediction of renal events.","volume":"21","author":"H Lambers Heerspink","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"519-26","DOI":"10.1046\/j.1365-2796.2001.00833.x","article-title":"Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity.","volume":"249","author":"H Hillege","year":"2001","journal-title":"J Intern Med."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"207-13","DOI":"10.1097\/01.hjr.0000133070.75016.1d","article-title":"Microalbuminuria, cardiovascular risk factors and cardiovascular morbidity in a British population: the EPIC-Norfolk population-based study.","volume":"11","author":"M Yuyun","year":"2004","journal-title":"Eur J Cardiovasc Prev Rehabil."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"2038-47","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States.","volume":"298","author":"J Coresh","year":"2007","journal-title":"JAMA."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"466-73","DOI":"10.1016\/s0272-6386(03)00742-x","article-title":"Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Tr\u00f8ndelag Health Study (HUNT), Norway.","volume":"42","author":"S Romundstad","year":"2003","journal-title":"Am J Kidney Dis."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"189-98","DOI":"10.1093\/ije\/dyh008","article-title":"Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study.","volume":"33","author":"M Yuyun","year":"2004","journal-title":"Int J Epidemiol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"1777-82","DOI":"10.1161\/01.cir.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.","volume":"106","author":"H Hillege","year":"2002","journal-title":"Circulation."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/ndt\/gfy242","article-title":"Renal albumin excretion in healthy young adults and its association with mortality risk in the US population.","volume":"375","author":"J Chong","year":"2018","journal-title":"Nephrol Dial Transplant."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"506-12","DOI":"10.1097\/HJH.0000000000000809","article-title":"Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals.","volume":"34","author":"F Tanaka","year":"2016","journal-title":"J Hypertens."},{"key":"ref-21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003245","article-title":"Urine Albumin\/Creatinine Ratio Below 30 mg\/g is a Predictor of Incident Hypertension and Cardiovascular Mortality.","volume":"5","author":"K Sung","year":"2016","journal-title":"J Am Heart Assoc."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"1794-801","DOI":"10.1093\/ndt\/gft031","article-title":"Isolated microalbuminuria indicates a poor medical prognosis.","volume":"28","author":"L Scheven","year":"2013","journal-title":"Nephrol Dial Transplant."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"2299-306","DOI":"10.1097\/HJH.0b013e328359a9f7","article-title":"Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years.","volume":"30","author":"N Takashima","year":"2012","journal-title":"J Hypertens."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"56-60","DOI":"10.1038\/hr.2014.117","article-title":"Slight increase in urinary albumin excretion within the normal range predicts incident hypertension in a community-based Japanese population: the Takahata study.","volume":"38","author":"A Hirayama","year":"2015","journal-title":"Hypertens Res."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"2100-5","DOI":"10.1681\/ASN.2006050517","article-title":"Microalbuminuria as an early marker for cardiovascular disease.","volume":"17","author":"D de Zeeuw","year":"2006","journal-title":"J Am Soc Nephrol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"267-72","DOI":"10.1053\/j.ackd.2014.03.007","article-title":"Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus.","volume":"21","author":"S Marshall","year":"2014","journal-title":"Adv Chronic Kidney Dis."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"219-27","DOI":"10.1046\/j.1523-1755.2001.00789.x","article-title":"Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold.","volume":"60","author":"N Chaturvedi","year":"2001","journal-title":"Kidney Int."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/bmj.38070.450891.FE","article-title":"Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study.","volume":"328","author":"P Hovind","year":"2004","journal-title":"BMJ."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"225-32","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).","volume":"63","author":"A Adler","year":"2003","journal-title":"Kidney Int."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"2342-50","DOI":"10.1681\/ASN.2013091004","article-title":"Renal outcomes in patients with type 1 diabetes and macroalbuminuria.","volume":"25","author":"I de Boer","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"412-20","DOI":"10.1001\/archinternmed.2011.16","article-title":"Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications cohort.","volume":"171","author":"I de Boer","year":"2011","journal-title":"Arch Intern Med."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"2309-20","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.","volume":"65","author":"D de Zeeuw","year":"2004","journal-title":"Kidney Int."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"2285-93","DOI":"10.1056\/NEJMoa021835","article-title":"Regression of microalbuminuria in type 1 diabetes.","volume":"348","author":"B Perkins","year":"2003","journal-title":"N Engl J Med."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"1399-408","DOI":"10.2337\/diabetes.49.9.1399","article-title":"The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?","volume":"49","author":"M Caramori","year":"2000","journal-title":"Diabetes."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"53-8","DOI":"10.1016\/j.mcna.2012.10.006","article-title":"Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook.","volume":"97","author":"J Dwyer","year":"2013","journal-title":"Med Clin North Am."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"653-61","DOI":"10.1053\/j.ajkd.2018.02.364","article-title":"Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.","volume":"72","author":"D Koye","year":"2018","journal-title":"Am J Kidney Dis."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"1861-3","DOI":"10.1001\/jama.1976.03270170027020","article-title":"The clinical course of diabetic nephropathy.","volume":"236","author":"M Kussman","year":"1976","journal-title":"JAMA."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"1636-42","DOI":"10.1056\/NEJM199611283352203","article-title":"Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group.","volume":"335","author":"R Nelson","year":"1996","journal-title":"N Engl J Med."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"982-8","DOI":"10.1016\/j.kint.2016.11.023","article-title":"Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.","volume":"91","author":"J Oellgaard","year":"2017","journal-title":"Kidney Int."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"884-95","DOI":"10.1053\/j.ajkd.2017.10.026","article-title":"Update on Diabetic Nephropathy: Core Curriculum 2018.","volume":"71","author":"K Umanath","year":"2018","journal-title":"Am J Kidney Dis."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"421-6","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.","volume":"286","author":"H Gerstein","year":"2001","journal-title":"JAMA."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"1813-21","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.","volume":"20","author":"T Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"1384-91","DOI":"10.2215\/CJN.13111215","article-title":"Diabetes, Kidney Disease, and Cardiovascular Outcomes in the Jackson Heart Study.","volume":"11","author":"M Afkarian","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"1942-9","DOI":"10.1093\/ndt\/gfy032","article-title":"Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: pooled analysis of four cohort studies.","volume":"33","author":"R Minutolo","year":"2018","journal-title":"Nephrol Dial Transplant."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"799-807","DOI":"10.1093\/ajh\/hpx051","article-title":"The Effects of Urinary Albumin and Hypertension on All-Cause and Cardiovascular Disease Mortality in Korea.","volume":"30","author":"M Seo","year":"2017","journal-title":"Am J Hypertens."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"1737-44","DOI":"10.1161\/CIRCULATIONAHA.110.005645","article-title":"Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States.","volume":"123","author":"E Ford","year":"2011","journal-title":"Circulation."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"947-53","DOI":"10.1038\/hr.2012.87","article-title":"Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women.","volume":"35","author":"A Fujiyoshi","year":"2012","journal-title":"Hypertens Res."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"101-5","DOI":"10.1161\/01.hyp.24.1.101","article-title":"Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension.","volume":"24","author":"A H\u00f8egholm","year":"1994","journal-title":"Hypertension."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"334-41","DOI":"10.1016\/0895-7061(95)00391-6","article-title":"Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the Hypertension and Ambulatory Recording Venetia Study (HARVEST Study).","volume":"9","author":"P Palatini","year":"1996","journal-title":"Am J Hypertens."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"1135-43","DOI":"10.1161\/01.hyp.30.5.1135","article-title":"Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications.","volume":"30","author":"R Pontremoli","year":"1997","journal-title":"Hypertension."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"445-59","DOI":"10.1053\/ajkd.2002.31388","article-title":"Microalbuminuria in the US population: third National Health and Nutrition Examination Survey.","volume":"39","author":"C Jones","year":"2002","journal-title":"Am J Kidney Dis."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"2317-24","DOI":"10.1097\/HJH.0b013e3282ef1c5f","article-title":"Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study.","volume":"25","author":"M B\u00f6hm","year":"2007","journal-title":"J Hypertens."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"947-53","DOI":"10.1097\/00004872-199408000-00013","article-title":"Ambulatory blood pressure and microalbuminuria in essential hypertension: role of circadian variability.","volume":"12","author":"J Redon","year":"1994","journal-title":"J Hypertens."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"23-9","DOI":"10.1093\/ajh\/7.1.23","article-title":"Diurnal variations of blood pressure and microalbuminuria in essential hypertension.","volume":"7","author":"S Bianchi","year":"1994","journal-title":"Am J Hypertens."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"1074-9","DOI":"10.1007\/bf02221684","article-title":"Circadian variation of blood pressure in patients with diabetic nephropathy.","volume":"35","author":"K Hansen","year":"1992","journal-title":"Diabetologia."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"1729-37","DOI":"10.2337\/dc16-0748","article-title":"Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease.","volume":"39","author":"G Ruiz-Hurtado","year":"2016","journal-title":"Diabetes Care."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"55-61","DOI":"10.1161\/HYPERTENSIONAHA.107.100727","article-title":"Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension.","volume":"51","author":"R Fagard","year":"2008","journal-title":"Hypertension."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"156-61","DOI":"10.1161\/01.HYP.0000170138.56903.7a","article-title":"Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study.","volume":"46","author":"E Dolan","year":"2005","journal-title":"Hypertension."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"937-43","DOI":"10.1038\/hr.2017.74","article-title":"White-coat and masked hypertension are associated with albuminuria in a general population: the Hisayama Study.","volume":"40","author":"J Hata","year":"2017","journal-title":"Hypertens Res."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"880-6","DOI":"10.1016\/j.amjhyper.2006.03.006","article-title":"Masked hypertension and target organ damage in treated hypertensive patients.","volume":"19","author":"M Tomiyama","year":"2006","journal-title":"Am J Hypertens."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"385-91","DOI":"10.1016\/j.amjhyper.2006.10.008","article-title":"Subclinical arterial damage in untreated masked hypertensive subjects detected by home blood pressure measurement.","volume":"20","author":"Y Matsui","year":"2007","journal-title":"Am J Hypertens."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"27-33","DOI":"10.1038\/jhh.2009.35","article-title":"Urinary albumin excretion is associated with true resistant hypertension.","volume":"24","author":"A Oliveras","year":"2010","journal-title":"J Hum Hypertens."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"1953-2041","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.","volume":"36","author":"B Williams","year":"2018","journal-title":"J Hypertens."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"399-404","DOI":"10.1038\/sj.jhh.1001408","article-title":"Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension.","volume":"16","author":"G Leoncini","year":"2002","journal-title":"J Hum Hypertens."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"993-1000","DOI":"10.1097\/00004872-199917070-00016","article-title":"Left ventricular geometry and function in patients with essential hypertension and microalbuminuria.","volume":"17","author":"R Pontremoli","year":"1999","journal-title":"J Hypertens."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"2780-7","DOI":"10.1093\/ndt\/gfl364","article-title":"Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONICA\/KORA Augsburg Echocardiographic Substudy.","volume":"21","author":"W Lieb","year":"2006","journal-title":"Nephrol Dial Transplant."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"249-54","DOI":"10.1038\/sj.jhh.1001379","article-title":"Microalbuminuria is associated with unfavourable cardiac geometric adaptations in essential hypertensive subjects.","volume":"16","author":"C Tsioufis","year":"2002","journal-title":"J Hum Hypertens."},{"key":"ref-68","first-page":"827-33","article-title":"Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria.","volume":"9","author":"R Bigazzi","year":"1995","journal-title":"J Hum Hypertens."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"1107-14","DOI":"10.1093\/ndt\/gfl733","article-title":"Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults.","volume":"22","author":"N Rodondi","year":"2007","journal-title":"Nephrol Dial Transplant."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"519-27","DOI":"10.1093\/ajh\/hpv130","article-title":"Relationship Between Carotid Atherosclerosis and Pulse Pressure with Renal Hemodynamics in Hypertensive Patients.","volume":"29","author":"G Geraci","year":"2016","journal-title":"Am J Hypertens."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"363-9","DOI":"10.1093\/eurheartj\/ehl394","article-title":"Albuminuria as risk factor for initiation and progression of carotid atherosclerosis in non-diabetic persons: the Troms\u00f8 Study.","volume":"28","author":"L J\u00f8rgensen","year":"2007","journal-title":"Eur Heart J."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"915-20","DOI":"10.1097\/00004872-199607000-00016","article-title":"Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension.","volume":"14","author":"G Cerasola","year":"1996","journal-title":"J Hypertens."},{"key":"ref-73","doi-asserted-by":"publisher","DOI":"10.3310\/hta9300","article-title":"Systematic review on urine albumin testing for early detection of diabetic complications.","volume":"9","author":"D Newman","year":"2005","journal-title":"Health Technol Assess."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"121-5","DOI":"10.1177\/174182679700400208","article-title":"Urinary albumin excretion and history of acute myocardial infarction in a cross-sectional population study of 2,613 individuals.","volume":"4","author":"J Jensen","year":"1997","journal-title":"Eur J Cardiovasc Prev Rehabil."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"32-5","DOI":"10.1161\/01.CIR.0000133312.96477.48","article-title":"Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes.","volume":"110","author":"K Klausen","year":"2004","journal-title":"Circulation."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"838-43","DOI":"10.14740\/jocmr2785w","article-title":"Microalbuminuria: Correlation With Prevalence and Severity of Coronary Artery Disease in Non-Diabetics.","volume":"9","author":"P Kumar Jha","year":"2017","journal-title":"J Clin Med Res."},{"key":"ref-77","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005539","article-title":"Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure.","volume":"6","author":"P Swoboda","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"ref-78","doi-asserted-by":"publisher","first-page":"2512-20","DOI":"10.1681\/ASN.2014101034","article-title":"Cause-Specific Deaths in Non-Dialysis-Dependent CKD.","volume":"26","author":"S Navaneethan","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"ref-79","first-page":"1-150","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","year":"2013","journal-title":"Kidney Int (Suppl.)."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"825-30","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.","volume":"158","author":"P Stevens","year":"2013","journal-title":"Ann Intern Med."},{"key":"ref-81","doi-asserted-by":"publisher","first-page":"1209-16","DOI":"10.1046\/j.1523-1755.1998.00874.x","article-title":"Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. \"Gruppo Italiano di Studi Epidemiologici in Nefrologia\" (GISEN).","volume":"53","author":"P Ruggenenti","year":"1998","journal-title":"Kidney Int."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"1941-9","DOI":"10.2215\/CJN.02720317","article-title":"Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease.","volume":"12","author":"K Sumida","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"ref-83","doi-asserted-by":"publisher","first-page":"1969-77","DOI":"10.2215\/CJN.02870316","article-title":"Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT\/EDIC Study.","volume":"11","author":"I de Boer","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"1079-88","DOI":"10.2215\/CJN.11511114","article-title":"Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View.","volume":"10","author":"H Lambers Heerspink","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"ref-85","doi-asserted-by":"publisher","first-page":"2055-64","DOI":"10.1681\/ASN.2014070688","article-title":"Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.","volume":"26","author":"H Heerspink","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"ref-86","doi-asserted-by":"publisher","first-page":"244-51","DOI":"10.1016\/j.kint.2016.09.037","article-title":"Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality.","volume":"91","author":"J Carrero","year":"2017","journal-title":"Kidney Int."},{"key":"ref-87","doi-asserted-by":"publisher","first-page":"1353-64","DOI":"10.1681\/ASN.2010091001","article-title":"Changes in albuminuria predict mortality and morbidity in patients with vascular disease.","volume":"22","author":"R Schmieder","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"ref-88","doi-asserted-by":"publisher","first-page":"2019-29","DOI":"10.1007\/s00125-014-3330-9","article-title":"Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies.","volume":"57","author":"R Schmieder","year":"2014","journal-title":"Diabetologia."},{"key":"ref-89","doi-asserted-by":"publisher","first-page":"51-61","DOI":"10.1053\/j.ajkd.2018.05.015","article-title":"Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.","volume":"73","author":"D Weiner","year":"2019","journal-title":"Am J Kidney Dis."},{"key":"ref-90","doi-asserted-by":"publisher","first-page":"2159-219","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).","volume":"34","author":"G Mancia","year":"2013","journal-title":"Eur Heart J."},{"key":"ref-91","doi-asserted-by":"publisher","first-page":"507-20","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).","volume":"311","author":"P James","year":"2014","journal-title":"JAMA."},{"key":"ref-92","doi-asserted-by":"publisher","first-page":"918-29","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease.","volume":"363","author":"L Appel","year":"2010","journal-title":"N Engl J Med."},{"key":"ref-93","doi-asserted-by":"publisher","first-page":"2103-16","DOI":"10.1056\/NEJMoa1511939","article-title":"A Randomized Trial of Intensive versus Standard Blood-Pressure Control.","volume":"373","author":"J Wright","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-94","doi-asserted-by":"publisher","first-page":"1498-505","DOI":"10.1001\/jamainternmed.2017.4377","article-title":"Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis.","volume":"177","author":"R Malhotra","year":"2017","journal-title":"JAMA Intern Med."},{"key":"ref-95","doi-asserted-by":"publisher","first-page":"821-31","DOI":"10.2215\/CJN.08660815","article-title":"Age and Outcomes Associated with BP in Patients with Incident CKD.","volume":"11","author":"C Kovesdy","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"ref-96","doi-asserted-by":"publisher","first-page":"1553-9","DOI":"10.2215\/CJN.11391114","article-title":"Systolic BP and Mortality in Older Adults with CKD.","volume":"10","author":"J Weiss","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"ref-97","doi-asserted-by":"publisher","first-page":"2673-82","DOI":"10.1001\/jama.2016.7050","article-title":"Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged \u226575 Years: A Randomized Clinical Trial.","volume":"315","author":"J Williamson","year":"2016","journal-title":"JAMA."},{"key":"ref-98","doi-asserted-by":"publisher","first-page":"1575-85","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus.","volume":"362","author":"W Cushman","year":"2010","journal-title":"N Engl J Med."},{"key":"ref-99","doi-asserted-by":"publisher","first-page":"2176-98","DOI":"10.1016\/j.jacc.2017.11.004","article-title":"Systematic Review for the 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"71","author":"D Reboussin","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"ref-100","doi-asserted-by":"publisher","first-page":"115-27","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.","volume":"7","author":"J Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref-101","doi-asserted-by":"publisher","first-page":"128-39","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.","volume":"7","author":"H Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref-102","doi-asserted-by":"publisher","first-page":"603-8","DOI":"10.1038\/nrcardio.2016.48","article-title":"Global cardiovascular protection in chronic kidney disease.","volume":"13","author":"G Ruiz-Hurtado","year":"2016","journal-title":"Nat Rev Cardiol."},{"key":"ref-103","doi-asserted-by":"publisher","first-page":"1689-97","DOI":"10.1097\/HJH.0000000000000991","article-title":"Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta-regression analysis.","volume":"34","author":"F Viazzi","year":"2016","journal-title":"J Hypertens."},{"key":"ref-104","doi-asserted-by":"publisher","first-page":"861-9","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345","author":"B Brenner","year":"2001","journal-title":"N Engl J Med."},{"key":"ref-105","doi-asserted-by":"publisher","first-page":"851-60","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.","volume":"345","author":"E Lewis","year":"2001","journal-title":"N Engl J Med."},{"key":"ref-106","doi-asserted-by":"publisher","first-page":"883-92","DOI":"10.1681\/ASN.2008070667","article-title":"Lowering blood pressure reduces renal events in type 2 diabetes.","volume":"20","author":"B de Galan","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"ref-107","doi-asserted-by":"publisher","first-page":"907-17","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.","volume":"364","author":"H Haller","year":"2011","journal-title":"N Engl J Med."},{"key":"ref-108","doi-asserted-by":"publisher","first-page":"1547-59","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events.","volume":"358","author":"S Yusuf","year":"2008","journal-title":"N Engl J Med."},{"key":"ref-109","doi-asserted-by":"publisher","first-page":"1892-903","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy.","volume":"369","author":"L Fried","year":"2013","journal-title":"N Engl J Med."},{"key":"ref-110","doi-asserted-by":"publisher","first-page":"2204-13","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes.","volume":"367","author":"H Parving","year":"2012","journal-title":"N Engl J Med."},{"key":"ref-111","doi-asserted-by":"publisher","first-page":"2641-50","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.","volume":"20","author":"U Mehdi","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"ref-112","doi-asserted-by":"publisher","first-page":"2283-92","DOI":"10.1517\/14656566.2015.1079623","article-title":"An update of the blockade of the renin angiotensin aldosterone system in clinical practice.","volume":"16","author":"D M\u00e1rquez","year":"2015","journal-title":"Expert Opin Pharmacother."},{"key":"ref-113","doi-asserted-by":"publisher","first-page":"611","DOI":"10.12688\/f1000research.9916.1","article-title":"The impact of antihypertensives on kidney disease [version 1; peer review: 2 approved].","volume":"6","author":"D Marquez","year":"2017","journal-title":"F1000Res."},{"key":"ref-114","doi-asserted-by":"publisher","first-page":"69-78","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.","volume":"64","author":"P Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol."},{"key":"ref-115","doi-asserted-by":"publisher","first-page":"2453-63","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.","volume":"34","author":"B Pitt","year":"2013","journal-title":"Eur Heart J."},{"key":"ref-116","doi-asserted-by":"publisher","first-page":"884-94","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.","volume":"314","author":"G Bakris","year":"2015","journal-title":"JAMA."},{"key":"ref-117","doi-asserted-by":"publisher","first-page":"211-21","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.","volume":"372","author":"M Weir","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-118","doi-asserted-by":"publisher","first-page":"222-31","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia.","volume":"372","author":"D Packham","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-119","doi-asserted-by":"publisher","first-page":"401-11","DOI":"10.1002\/phar.1906","article-title":"Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.","volume":"37","author":"C Meaney","year":"2017","journal-title":"Pharmacotherapy."},{"key":"ref-120","doi-asserted-by":"publisher","first-page":"2117-28","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.","volume":"373","author":"B Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-121","doi-asserted-by":"publisher","first-page":"323-34","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.","volume":"375","author":"C Wanner","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-122","doi-asserted-by":"publisher","first-page":"644-57","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.","volume":"377","author":"B Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"ref-123","doi-asserted-by":"publisher","first-page":"2295-306","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.","volume":"380","author":"V Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"ref-124","doi-asserted-by":"publisher","first-page":"311-22","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.","volume":"375","author":"S Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-125","doi-asserted-by":"publisher","first-page":"1834-44","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.","volume":"375","author":"S Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-126","doi-asserted-by":"publisher","first-page":"839-48","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes.","volume":"377","author":"J Mann","year":"2017","journal-title":"N Engl J Med."},{"key":"ref-127","doi-asserted-by":"publisher","first-page":"527-35","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy.","volume":"21","author":"J Mann","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"ref-128","doi-asserted-by":"publisher","first-page":"763-72","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.","volume":"22","author":"D Kohan","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"ref-129","doi-asserted-by":"publisher","first-page":"1083-93","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.","volume":"25","author":"D de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"ref-130","doi-asserted-by":"publisher","first-page":"1937-47","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.","volume":"393","author":"H Heerspink","year":"2019","journal-title":"Lancet."},{"key":"ref-131","doi-asserted-by":"publisher","first-page":"117-24","DOI":"10.7326\/0003-4819-145-2-200607180-00009","article-title":"Meta-analysis: the effect of statins on albuminuria.","volume":"145","author":"K Douglas","year":"2006","journal-title":"Ann Intern Med."},{"key":"ref-132","doi-asserted-by":"publisher","first-page":"1449-61","DOI":"10.1517\/14656566.2015.1053464","article-title":"Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?","volume":"16","author":"V Athyros","year":"2015","journal-title":"Expert Opin Pharmacother."},{"key":"ref-133","doi-asserted-by":"publisher","first-page":"74-83","DOI":"10.1016\/j.phrs.2016.01.005","article-title":"The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis.","volume":"105","author":"Z Zhang","year":"2016","journal-title":"Pharmacol Res."},{"key":"ref-134","doi-asserted-by":"publisher","first-page":"2061-71","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis.","volume":"60","author":"M Jun","year":"2012","journal-title":"J Am Coll Cardiol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-1659\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1659\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1659\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T08:02:55Z","timestamp":1611216175000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-1659\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,19]]},"references-count":134,"URL":"https:\/\/doi.org\/10.12688\/f1000research.17212.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.18821.r47436","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.18821.r53131","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,19]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-1659\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.18821.r53131, Peter Rossing, Steno Diabetes Center Copenhagen, Gentofte, Denmark, 19 Sep 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1659\/v1#referee-response-53131","order":0,"name":"referee-response-53131","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.18821.r47436, Chi-yuan Hsu, Division of Nephrology, University of California, San Francisco, San Francisco, CA, USA, 19 Sep 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1659\/v1#referee-response-47436","order":1,"name":"referee-response-47436","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}